Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Benazepril Hydrochloride
VetViva Richter GmbH
QC09AA07
Benazepril Hydrochloride
Film-coated tablet
POM-V - Prescription Only Medicine – Veterinarian
Cats, Dogs
Cardio Vascular ACE inhibitor
Authorized
2013-02-11
Revised: January 2024 AN: 03431/2022 Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 5 mg, film-coated tablets for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Benazepril hydrochloride 5 mg (equivalent to benazepril 4.6 mg) EXCIPIENTS: QUALITATIVE COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS QUANTITATIVE COMPOSITION IF THAT INFORMATION IS ESSENTIAL FOR PROPER ADMINISTRATION OF THE VETERINARY MEDICINAL PRODUCt Lactose monohydrate Cellulose microcrystalline Starch pregelatinised Castor oil hydrogenated Crospovidone Silica colloidal anhydrous Coating: Macrogol poly(vinyl alcohol) grafted copolymer Poly(vinyl alcohol) Silica colloidal anhydrous Talc Macrogol 6000 Titanium dioxide (E171) Iron oxide yellow (E172) 0.52 mg 0.06 mg Light yellow, oval divisible film-coated tablets scored on both sides. 3. CLINICAL INFORMATION 3.1 TARGET SPECIES Dogs, cats Revised: January 2024 AN: 03431/2022 Page 2 of 8 3.2 INDICATIONS FOR USE FOR EACH TARGET SPECIES Dogs: Treatment of congestive heart failure. Cats: Reduction of proteinuria associated with chronic kidney disease. 3.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure. Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis. Do not use in pregnancy or lactation (see section 3.7). 3.4 SPECIAL WARNINGS None. 3.5 SPECIAL PRECAUTIONS FOR USE Special precautions for safe use in the target species: No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy. The efficacy and safety of the veterinary medicinal product has not been established in dogs and cats below 2.5 kg body weight. Specia Read the complete document